Adaptive Biotechnologies (ADPT) stock swings after earnings as MRD guidance, insider sale draw scrutiny
Adaptive Biotechnologies shares fell 5.2% to $15.61 Friday after Q4 revenue jumped 51% to $71.7 million and the company forecast 2026 MRD revenue of $255–$265 million. CEO Chad Robins disclosed selling 124,998 shares on Feb. 2. BTIG raised its price target to $22. The stock traded between $17.69 and $15.08 during the session.